Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria

Heart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced cardiovascular mortality and hospitalization for HF compared to placebo in patients with chronic HF, and reduced ejection fracti...

Descripción completa

Detalles Bibliográficos
Autores principales: Camps-Vilaró, Anna, Delgado-Jiménez, Juan F., Farré, Núria, Tizón-Marcos, Helena, Álvarez-García, Jesús, Cinca, Juan, Dégano, Irene R., Marrugat, Jaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408645/
https://www.ncbi.nlm.nih.gov/pubmed/32635219
http://dx.doi.org/10.3390/jcm9072089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408645/
https://www.ncbi.nlm.nih.gov/pubmed/32635219
http://dx.doi.org/10.3390/jcm9072089

Ejemplares similares